Dean Kereiakes, MD, was the principal investigator of a convalescent plasma protocol that utilized antibodies of those who had recovered from COVID-19 to treat the sickest of patients with the disease. Partnering with David Oh, MD, of Hoxworth Blood Center, Dr. Kereiakes developed this treatment, and received FDA approval, in April, well before specific antiviral drugs were widely available for COVID-19. The protocol went on to be used by other major hospital systems in the region and saw success in turning around the conditions of those most afflicted.

"There is no worse feeling than watching someone deteriorating in front of your eyes and feeling helpless and hopeless," Dr. Kereiakes said. "We had to have something readily available. We needed to have at least one weapon to help make a difference in the care of patients."